Bonraybio CoTPE:6955 65 EV-to-FCF is 37.07 as of Jul. 07, 2026, which is 33% below its 10-year median of 55.72. GuruFocus rates TPE:6955 with a GF Score™ of 65/100 and a GF Value™ of NT$184.74 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 417 Medical Devices & Instruments companies, Bonraybio Co ranks worse than 67.15% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bonraybio Co's Enterprise Value is NT$2,437.2 Mil.
Bonraybio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$65.8 Mil. Therefore, Bonraybio Co's EV-to-FCF for today is 37.07.
The historical rank and industry rank for Bonraybio Co's EV-to-FCF or its related term are showing as below:
TPE:6955'
s EV-to-FCF Range Over the Past 10 Years
Min: -194.18 Med: 55.72 Max: 480.46
Current: 37.07
During the past 6 years, the highest EV-to-FCF of Bonraybio Co was 480.46. The lowest was -194.18. And the median was 55.72.
TPE:6955's EV-to-FCF is ranked worse than 67.15% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 23.54
vs TPE:6955: 37.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bonraybio Co's PE Ratio (TTM) for today is calculated as:
Bonraybio Co's share price for today is NT$120.50.
Bonraybio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4.127.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bonraybio Co EV-to-FCF Related Terms
Bonraybio Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bonraybio Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bonraybio Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonraybio Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonraybio Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bonraybio Co's EV-to-FCF falls into.
Bonraybio Co's current Enterprise Value is NT$2,437.2 Mil.
Bonraybio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$65.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonraybio Co (TPE:6955) has a EV-to-FCF of 37.07 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bonraybio Co and its competitors. This is 33% below median its historical median of 55.72. According to the industry distribution chart, Bonraybio Co ranks #280 out of 417 companies in the Medical Devices & Instruments industry, placing it in the top 67.1%.
Is Bonraybio Co's EV-to-FCF too high?
Bonraybio Co's current EV-to-FCF of 37.07 is 33% below median its 10-year median of 55.72. The Medical Devices & Instruments industry median EV-to-FCF is 23.54. Bonraybio Co's value of 37.07 is 57.5% above this industry median. Based on the distribution chart, Bonraybio Co ranks #280 out of 417 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bonraybio Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonraybio Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bonraybio Co ranks #280 out of 417 companies for EV-to-FCF. This places Bonraybio Co in the lower half of its industry. The industry median EV-to-FCF is 23.54. Bonraybio Co's value of 37.07 is 57.5% above this benchmark. While the company's 10-year median is 55.72 vs. the industry median of 23.54, Bonraybio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.54, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonraybio Co's current EV-to-FCF of 37.07 is 57.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bonraybio Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonraybio Co's current EV-to-FCF is 37.07, which is 33% below median its own 10-year median of 55.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonraybio Co stock overvalued right now?
Based on GuruFocus' analysis, Bonraybio Co (TPE:6955) is currently considered Possible Value Trap. The stock's GF Value™ is NT$184.74, compared to a current price of NT$120.50 — trading 34.8% below its estimated fair value. The current EV-to-FCF is 37.07, which is 33% below median its 10-year median of 55.72 and 57.5% above the Medical Devices & Instruments industry median of 23.54. Bonraybio Co's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bonraybio Co (TPE:6955), the current EV-to-FCF is 37.07 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonraybio Co (TPE:6955) Overvalued in 2026?
Based on GuruFocus' analysis, Bonraybio Co stock appears to be undervalued.
The current stock price of NT$120.50 is trading 34.8% below its estimated GF Value™ of NT$184.74.
GuruFocus considers Bonraybio Co to be Possible Value Trap.
Key valuation signals for TPE:6955:
EV-to-FCF: 37.07 (33% below median its 10-year median of 55.72)
GF Value™: NT$184.74 vs. price of NT$120.50 (34.8% below fair value)
Industry Position: 57.5% above the Medical Devices & Instruments median (#280 of 417)
No single metric tells the full story. See the TPE:6955 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonraybio Co Ltd engages in research, development, and manufacturing of vitro diagnostic devices. The firm produces semen quality analyzers and Semen Analysis Systems for the clinic.
65GF Score
Get the complete analysis for TPE:6955
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6955 has been successfully added to your 
